Patients suffering from dental infections and concurrently using immunosuppressive medication are at increased risk of developing systemic streptococcal infections. Tocilizumab is a novel therapeutic agent targeting interleukin-6. We describe a case of streptococcal lung abscesses from a dental focus after use of tocilizumab for treatment of Takayasu Arteritis.

, ,
Clinical and Experimental Rheumatology
Department of Virology

de Kruif, M.D, van Gorp, E.C.M, Bel, E.H, Gerlag, D.M, & Kunst, P.W. (2012). Streptococcal lung abscesses from a dental focus following tocilizumab: A case report. Clinical and Experimental Rheumatology, 30(6), 951–953. Retrieved from